TET2 mutations in particular enhance expression and release of pro‐inflammatory cytokines such as IL‐1β, activating the NLRP3 inflammasome thereby driving atherosclerosis [170, 171, 172] and NLRP3‐inhibition rescues adverse remodeling and cardiac hypertrophy [173]. This evidence concerns the gene NLRP3 and cardiac hypertrophy.